PEMF for
Polymyalgia Rheumatica.

July 2026 · 10 min read · Rheumatology Protocol

What Is Polymyalgia Rheumatica?

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease characterized by aching and morning stiffness in the shoulder girdle, neck, and hip girdle (pelvic area). It is the most common inflammatory rheumatic condition in adults over 50, with incidence peaking in the 70–79 age group. Women are affected approximately twice as often as men. Despite its high prevalence, PMR remains under-recognized in settings without dedicated rheumatology access — a pattern very much present in the Philippines.

PMR is driven primarily by interleukin-6 (IL-6) overproduction from synovial and bursal tissue. The hallmark is severe bilateral shoulder and hip pain that appears over days to weeks, accompanied by dramatic ESR elevation (often >50 mm/h) and CRP elevation. Most patients cannot raise their arms above shoulder height or rise from a chair without assistance during active disease.

The Corticosteroid Dependency Problem

Low-dose corticosteroids (prednisolone 12.5–25 mg/day tapering) remain the standard of care for PMR, producing rapid and dramatic symptom relief — often within 24–72 hours. However, this apparent success conceals a serious clinical problem: patients typically require corticosteroid therapy for 1–3 years, and a significant proportion (25–30%) relapse when tapering is attempted too aggressively. Prolonged corticosteroid use in elderly patients carries compounding risks: osteoporosis, hyperglycemia, hypertension, immunosuppression, and adrenal insufficiency. In a Philippine context where patients frequently have baseline hypertension and diabetes, these risks are amplified.

The unmet need is a non-pharmacological adjunct that can suppress local inflammatory burden — reducing relapse risk during corticosteroid taper — without systemic side effects. PEMF addresses this at the tissue level.

How PEMF Targets PMR Pathophysiology

The inflammatory cascade in PMR centers on synovial and bursal IL-6 production, NF-κB activation, and macrophage polarization toward a pro-inflammatory (M1) phenotype. PEMF interrupts this cascade through four documented mechanisms:

1. NF-κB pathway suppression: PEMF exposure at 25–75 Hz reduces nuclear translocation of NF-κB, the master transcription factor governing IL-1β, IL-6, TNF-α, and COX-2 expression. This is the same pathway targeted by IL-6 receptor inhibitors (tocilizumab) in refractory PMR.
2. Macrophage polarization shift: Pulsed electromagnetic fields promote M1→M2 macrophage transition in inflamed tissue, shifting the microenvironment from pro-inflammatory cytokine production toward anti-inflammatory and pro-resolution mediators (IL-10, TGF-β).
3. Adenosine-A2A receptor activation: PEMF upregulates cell-surface A2A adenosine receptors, which directly suppress synovial mast cell degranulation and T-cell activation — reducing the bursal inflammatory load that generates PMR symptoms.
4. Nitric oxide and microcirculatory improvement: PEMF increases endothelial NO synthase activity, improving periarticular microcirculation and reducing inflammatory edema in shoulder and hip bursae.

Supporting Evidence

Direct RCT evidence for PEMF in PMR specifically is limited — the condition has historically been treated pharmacologically with little need for adjunctive physical modalities. However, the evidence base for PEMF in IL-6-mediated inflammatory arthropathies and large-joint bursitis is directly applicable:

• PMC11914662 (2025 multicenter RCT, n=91): 36% pain reduction vs. 10% standard care (p<0.0001); 55% reduction in medication consumption. Included patients with inflammatory arthritis components alongside mechanical back pain — the anti-inflammatory effect was pronounced in the inflammatory subgroup.
• Rheumatoid arthritis PEMF RCTs (multiple, 1990–2023): Consistent 25–40% joint pain and morning stiffness reduction in IL-6-mediated inflammatory conditions. PMR's pathophysiology is sufficiently similar (bursal > joint, same cytokine drivers) to extrapolate these findings.
• PEMF for shoulder bursitis (Binder et al.): Statistically significant improvement in shoulder abduction range of motion and pain VAS after 12 sessions in subacromial bursitis patients — directly relevant to the subdeltoid bursitis component of PMR.
• Anti-fibrotic and anti-cytokine meta-analyses: Pooled analyses of PEMF in osteoarthritis and inflammatory joint disease consistently document IL-6 and CRP reduction at tissue level, providing mechanistic support for PMR application.

Clinical Protocol: PEMF for PMR

Phase 1 — Acute Inflammatory Control (Weeks 1–4)

• Frequency: 25–50 Hz (anti-inflammatory range)
• Intensity: Medium (clinic-grade system: 40–60 mT peak field)
• Application areas: Bilateral shoulder girdle (deltoid/subacromial/acromioclavicular) + bilateral hip girdle (greater trochanteric/iliopsoas bursae)
• Session duration: 35–45 minutes
• Frequency: 2–3 sessions per week
• Goal: Reduce inflammatory burden to facilitate faster prednisolone taper

Phase 2 — Taper Support (Weeks 5–12)

• Frequency: 10–25 Hz (neuromodulatory/pain range added)
• Session duration: 30–40 minutes
• Frequency: 1–2 sessions per week (coordinated with rheumatologist taper schedule)
• Goal: Maintain symptom control as corticosteroid dose decreases; prevent relapse

Phase 3 — Maintenance (Month 4 onward)

• Frequency: 1 session per week or biweekly
• Goal: Sustained remission, ESR/CRP monitoring

Outcome Tracking

• Pain VAS (bilateral shoulder + hip) at each visit
• Morning stiffness duration (minutes)
• ESR and CRP at 4-week intervals (coordinate with rheumatologist)
• HAQ-DI (Health Assessment Questionnaire – Disability Index) at weeks 0, 6, 12

PEMF vs. Standard PMR Management Options

Contraindications

• Active cardiac pacemaker or implanted defibrillator — absolute contraindication
• Pregnancy — avoid treatment during active disease in pregnancy (rare in PMR age group)
• Active malignancy in treatment area — defer until oncology clearance
• Giant cell arteritis (GCA) with active cranial involvement — PMR and GCA are related conditions; cranial GCA requires urgent high-dose steroid ± biologic therapy; PEMF cannot substitute for vascular emergency management
• Metallic implants in treatment field — assess case by case; joint replacements generally tolerated at clinical field strengths

The Philippines Context

The Philippines has a rapidly aging population: the 60+ cohort is projected to reach 11.6 million by 2030 (PSA). PMR prevalence in this demographic is estimated at 0.5–1.0% of adults over 50, suggesting 250,000–500,000 potential PMR patients nationally — the majority currently managed with corticosteroids alone due to limited rheumatology access outside Metro Manila. Clinic chains with PEMF capability can position as rheumatology-adjacent services for this underserved segment, with referral relationships from internists, family physicians, and general practitioners who manage the bulk of PMR cases.

The typical PMR patient completes 8–16 PEMF sessions over a 3-month taper window, representing ₱12,000–₱40,000 in clinic revenue per patient — with strong likelihood of maintenance session return if taper is managed collaboratively.

Multidisciplinary Integration

PEMF for PMR should be coordinated with the patient's managing physician or rheumatologist. The PEMF protocol does not alter prednisolone dosing decisions — those remain with the prescribing clinician. However, objective improvement metrics (VAS, morning stiffness duration, functional capacity) should be communicated to the physician to inform taper pacing. This collaborative model positions the PEMF clinic as a value-adding partner in complex inflammatory disease management, not a competing service.